comparemela.com

American Society For Nephrology News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights

– Patient recruitment underway in ENERGY-3 Pivotal Trial of INZ-701 in pediatric patients with ENPP1 Deficiency; topline data expected mid-2025 –

United statesStefan rileyDouglasa trecoInozyme pharmaMatt peraPamerican society for boneDrug administrationInozyme pharma incDevelopment rd expensesAmerican society for nephrologyPaediatric committee of the european medicines agencyMineral researchCorporate communicationsAmerican society of nephrology kidney weekExchange commissionAmerican society

Redx Pharma s 10th drug candidate to target chronic kidney disease after promising preclinical results

Redx Pharma PLC (AIM:REDX) has unveiled promising preclinical data for RXC009, a potential new treatment for chronic kidney disease (CKD). At the recent.

United statesRichard armerAmerican society for nephrologyRedx pharmaAmerican society

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Q3 2023 Earnings Call Transcript

Operator: Greetings. Welcome to Aurinia Pharmaceuticals Third Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.

United kingdomUnited statesJamie harrellToni braxtonFarzin haqueJoe millerMaury raycroftPeter greenleafJoseph schwartzAurinia pharmaceuticals incWelcome to aurinia pharmaceuticals third quarterAmerican college of rheumatologyDisease awareness campaign get uncomfortableAurinia allianceInvestor relations for aurinia pharmaceuticalsOtsuka pharmaceuticals

Doctors push to include dialysis machines in emergency stockpile

Dialysis patients have a significantly higher risk of death in the 30 days following a hurricane compared to non-storm periods.

United statesNew yorkLake houstonNew jerseyLavarne burtonAriel brighamPeter kotankoJeffrey silberzweigDavid goldfarbMary denigan macauleyJose arrascueJennifer friedmanCenters for diseaseAmerican society for nephrologyEmergency partnership initiativeUs strategic national stockpile

Synlogic Presents Data on Hyperoxaluria Program at American Society of Nephrology Kidney Week 2021

/PRNewswire/ Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced.

United kingdomUnited statesSynlogic incPrnewswire synlogic incAmerican society for nephrologyAmerican societyKidney weekRelationship betweenUrinary oxalateIncident chronic kidney disease among patientsUnderlying gastrointestinal diseaseProof of concept studyOxalate consuming synthetic biotic medicineEnteric hyperoxaluriaRoux eny surgerySynthetic biotic

vimarsana © 2020. All Rights Reserved.